Published in Medical Letter on the CDC and FDA, January 16th, 2005
Captique is the newest hyaluronic acid entry into the U.S. dermal filler marketplace. It is indicated for the correction of moderate-to-severe facial wrinkles and is manufactured by Genzyme. Inamed is Genzyme's exclusive U.S. marketing and distribution partner for Captique.
"We are excited with the FDA's approval of Captique, our initial nonanimal stabilized hyaluronic acid-based dermal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA